Highlight
- Left atrial (LA) dysfunction, notably impaired LA strain, is prevalent in transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and independently predicts adverse outcomes including mortality, heart failure hospitalizations, and atrial fibrillation.
- LA volume index (LAVi), a traditional measure of atrial remodeling, was not predictive of clinical events in this population, highlighting the superior prognostic value of strain-based functional assessment.
- Vutrisiran, an RNA silencing therapy targeting transthyretin, mitigated progressive LA functional decline over 30 months, suggesting a beneficial impact on atrial myopathy beyond its known effects on ventricular parameters.
- LA strain did not modify the treatment effect of vutrisiran, supporting its consistent benefits across varying degrees of atrial dysfunction in ATTR-CM.
Specialty calculators
For clinical reference; use professional judgment.

